Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup K Amatya, Mallorie H Fiero, Erik W Bloomquist, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 20, 2006
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvantWillem W Overwijk, Karin E de Visser, Felicia H Tirion, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
The Journal of Experimental Medicine|August 20, 2003
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cellsWillem W Overwijk, Marc R Theoret, Steven E Finkelstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or FusionsDiana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Cancer Discovery|December 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug DevelopmentJoshua M Donaldson, Marjilla Seddiq, Michael J Fusco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup K Amatya, Mallorie H Fiero, Erik W Bloomquist, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 20, 2006
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvantWillem W Overwijk, Karin E de Visser, Felicia H Tirion, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
The Journal of Experimental Medicine|August 20, 2003
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cellsWillem W Overwijk, Marc R Theoret, Steven E Finkelstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or FusionsDiana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Cancer Discovery|December 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug DevelopmentJoshua M Donaldson, Marjilla Seddiq, Michael J Fusco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Pageof 11